168 related articles for article (PubMed ID: 37795794)
21. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
22. Combined bulk RNA-seq and single-cell RNA-seq identifies a necroptosis-related prognostic signature associated with inhibitory immune microenvironment in glioma.
Wan S; Moure UAE; Liu R; Liu C; Wang K; Deng L; Liang P; Cui H
Front Immunol; 2022; 13():1013094. PubMed ID: 36466844
[TBL] [Abstract][Full Text] [Related]
23. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
24. Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
Peng Y; Liu H; Wu Q; Wang L; Yu Y; Yin F; Feng C; Ren X; Liu T; Chen L; Zhu H
BMC Cancer; 2023 Jun; 23(1):596. PubMed ID: 37380984
[TBL] [Abstract][Full Text] [Related]
25. Bulk and Single-Cell Transcriptome Analyses Revealed That the Pyroptosis of Glioma-Associated Macrophages Participates in Tumor Progression and Immunosuppression.
Li L; Wu L; Yin X; Li C; Hua Z
Oxid Med Cell Longev; 2022; 2022():1803544. PubMed ID: 36199426
[TBL] [Abstract][Full Text] [Related]
26. Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction.
Li H; Sun X; Zhao Y; Zhang C; Jiang K; Ren J; Xing L; He M
BMC Cancer; 2023 Jun; 23(1):528. PubMed ID: 37296415
[TBL] [Abstract][Full Text] [Related]
27.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
28. A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma.
Luo X; Wang Q; Tang H; Chen Y; Li X; Chen J; Zhang X; Li Y; Sun J; Han S
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676646
[No Abstract] [Full Text] [Related]
29. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
30. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
31. Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas.
Li J; Zhang S; Chen S; Yuan Y; Zuo M; Li T; Wang Z; Liu Y
Front Immunol; 2023; 14():1021678. PubMed ID: 36860853
[TBL] [Abstract][Full Text] [Related]
32. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
33.
Hu Z; Qu S
Front Immunol; 2021; 12():683572. PubMed ID: 34267752
[TBL] [Abstract][Full Text] [Related]
34. Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages.
Liu Y; Yao R; Shi Y; Liu Y; Liu H; Liu J; Guan Y; Yao Y; Chen L
Front Immunol; 2022; 13():845223. PubMed ID: 35350788
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
36. NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma.
Miftah H; Naji O; Ssi SA; Ghouzlani A; Lakhdar A; Badou A
Front Immunol; 2023; 14():1139268. PubMed ID: 37575237
[TBL] [Abstract][Full Text] [Related]
37. Polo-like kinase 1 is related with malignant characteristics and inhibits macrophages infiltration in glioma.
Luo L; Zhang XY; Zhen YW; Guo GC; Peng DZ; Wei C; Pei DL; Yu B; Ji YC; Liu XZ; Han L; Zhang ZY
Front Immunol; 2022; 13():1058036. PubMed ID: 36618405
[TBL] [Abstract][Full Text] [Related]
38. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a glioma-associated mesenchymal stem cell-related gene prognostic index for predicting prognosis and guiding individualized therapy in glioma.
Peng Z; Wu Y; Wang J; Gu S; Wang Y; Xue B; Fu P; Xiang W
Stem Cell Res Ther; 2023 Apr; 14(1):56. PubMed ID: 37005685
[TBL] [Abstract][Full Text] [Related]
40. Matrix Remodeling-Associated Protein 8 as a Novel Indicator Contributing to Glioma Immune Response by Regulating Ferroptosis.
Xu Z; Chen X; Song L; Yuan F; Yan Y
Front Immunol; 2022; 13():834595. PubMed ID: 35281049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
